Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;7(12):e2452158.
doi: 10.1001/jamanetworkopen.2024.52158.

Breast Cancer Susceptibility Gene Sequence Variations and Development of Contralateral Breast Cancer

Anne S Reiner  1 , Gordon P Watt  1 , Kathleen E Malone  2 , Charles F Lynch  3 , Esther M John  4   5   6 , Julia A Knight  7   8 , Meghan Woods  1 , Xiaolin Liang  1 , Marc Tischkowitz  9 , David V Conti  10 , Mark E Robson  11 , Lene Mellemkjær  12 , Sharon N Teraoka  13 , Patrick Concannon  13 , Jonine L Bernstein  1
Affiliations

Breast Cancer Susceptibility Gene Sequence Variations and Development of Contralateral Breast Cancer

Anne S Reiner et al. JAMA Netw Open. .

Abstract

Importance: Heterogeneity in development of estrogen receptor (ER)-specific first primary breast cancer exists due to deleterious germline variants in moderate- to high-penetrance breast cancer susceptibility genes, but it is unknown if these associations occur in ER-specific CBC.

Objective: To determine the association of deleterious germline variants in breast cancer susceptibility genes with ER-specific CBC development and whether ER status of the first primary breast cancer modifies these associations.

Design, setting, and participants: This case-control study included CBC cases and matched unilateral breast cancer controls from The Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study, a population-based case-control study. Eligible women were diagnosed between 1985 and 2000 with data and biospecimens collected from 2001 to 2004. Eligible participants were women younger than 55 years at first invasive breast cancer diagnosis. Participants were matched on age, diagnosis year, cancer registry region, and race and ethnicity, and countermatched on radiation treatment. For cases, CBC occurred 1 year or more following first breast cancer diagnosis. Analyses were performed from May to October 2024.

Exposures: CHEK2 1100delC and deleterious variants in ATM, BRCA1, and BRCA2.

Main outcome and measure: Development of CBC, measured as a rate ratio (RR).

Results: A total of 1290 women were included in analysis (median [IQR] age at first diagnosis, 47 [42-51] years). The ER-positive CBC rate for women with deleterious ATM variants was 4 times higher than for women without deleterious ATM variants (RR, 4.84; 95% CI, 1.11-21.08; P = .04); no women with ER-negative CBC carried deleterious ATM variants. The ER-positive CBC rates for women with deleterious variants in BRCA2 or CHEK2 1100delC were 5 to 6 times higher than for women without deleterious variants in BRCA2 or CHEK2 1100delC, respectively (BRCA2: RR, 5.88; 95% CI, 2.61-13.26, P < .001; CHEK2 1100delC: RR, 6.06; 95% CI, 1.26-29.04; P = .02). The ER-negative CBC rate for women with deleterious BRCA1 variants was 26 times higher than for women without deleterious BRCA1 variants (RR, 26.16; 95% CI, 8.01-85.44; P < .001). First primary breast cancer ER status did not modify associations between deleterious variants and ER-specific CBC development.

Conclusions and relevance: In this case-control study of CBC, deleterious variants in breast cancer susceptibility genes were differentially associated with ER-specific CBC development. Germline variation profile may inform estimates of outcomes for ER-specific CBC subtypes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Tischkowitz reported receiving grant support by the National Institute for Health and Care Research Cambridge Biomedical Research Centre outside the submitted work. Dr Concannon reported holding stock for Amgen outside the submitted work. Dr Teraoka reported holding stock for Amgen outside the submitted work. No other disclosures were reported.

Comment in

  • doi: 10.1001/jamanetworkopen.2024.52107

References

    1. Johnson N, Fletcher O, Palles C, et al. . Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet. 2007;16(9):1051-1057. doi:10.1093/hmg/ddm050 - DOI - PubMed
    1. CHEK2 Breast Cancer Case-Control Consortium . CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 2004;74(6):1175-1182. doi:10.1086/421251 - DOI - PMC - PubMed
    1. Fletcher O, Johnson N, dos Santos Silva I, et al. ; kConFab Investigators; AOCS Group; GENICA Consortium; Breast Cancer Association Consortium . Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2143-2151. doi:10.1158/1055-9965.EPI-10-0374 - DOI - PMC - PubMed
    1. Renwick A, Thompson D, Seal S, et al. ; Breast Cancer Susceptibility Collaboration (UK) . ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38(8):873-875. doi:10.1038/ng1837 - DOI - PubMed
    1. Malone KE, Begg CB, Haile RW, et al. . Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28(14):2404-2410. doi:10.1200/JCO.2009.24.2495 - DOI - PMC - PubMed

Publication types